zur Navigation zum Inhalt
 
Endokrinologie 12. April 2016

Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer

In recent years, new therapeutic options have brought improvements in the treatment of metastatic, castration-resistant prostate cancer. Targeted Hormone Therapy (THT) represents a novel therapeutic component for which recent studies have shown a maximum benefit in the time between failure of androgen deprivation therapy (patient is metastatic and still pain-free) and prior to chemotherapy. Prostate cancer experts of the Austrian Society of Urology and Andrology (ÖGU), the Working Group for Urologic Oncology as part of the ÖGU, and the Professional Association of Austrian Urologists (BvU) have developed recommendations for the treatment of patients with asymptomatic or mildly symptomatic metastatic, castration-resistant prostate cancer. The definition of failure of classical hormonal therapy has been based on the guidelines of the German Society of Urology (Deutsche Gesellschaft für Urologie, DGU) and the European Association of Urology (EAU). Criteria for the initiation of treatment with hormonal or chemotherapy include:

Priv.-Doz. Dr. Anton Ponholzer, Prim. Dr. Wolfgang Loidl, Priv.-Doz. Dr. Jasmin Bektic, Dr. Karl Dorfinger, Dr. Stephan Hruby, Prim. Dr. Klaus Jeschke, Ao. Univ.-Prof. Dr. Gero Kramer, Prim. Univ.-Prof. Dr. Steffen Krause, Dr. Georg Ludvik, Prof. Priv.-Doz. Dr. Mesut Remzi, Dr. Michael Roider, Dr. Franz Stoiber, Wiener klinische Wochenschrift 3/4/2016

Volltext dieses Beitrags / entire article auf SpringerLink

Zu diesem Thema wurden noch keine Kommentare abgegeben.

Mehr zum Thema

<< Seite 1 >>

Medizin heute

Aktuelle Printausgaben